How do “historic” vaccines fail when new strains emerge quickly?

Question

Accepted Answer

Historic Vaccines Struggle Against Evolving Viral Strains Due to Their Reactive Nature

Traditional vaccines are considered "historic" because they are developed based on past virus strains. This reactive approach means that by the time a vaccine is ready, the virus may have already mutated into new strains, rendering the vaccine less effective. This constant "chasing" of the virus by vaccine development highlights a fundamental limitation in addressing rapidly evolving pathogens.
Viral Mutation Outpaces Traditional Vaccine Development Timelines

The inherent nature of viruses involves rapid mutation, a process driven by errors during replication. When a virus infects a host, its genetic material is copied. These copying processes are not always perfect, leading to small changes, or mutations, in the viral RNA or DNA. Over time, these accumulated mutations can result in new strains that possess different characteristics, including the ability to evade the immune response targeted by existing vaccines. For instance, the influenza virus is well-known for its frequent antigenic drift, necessitating annual vaccine updates.
The Ebola Outbreak as a Case Study of Delayed Response

The 2013-2016 Ebola outbreak in West Africa serves as a stark illustration of how traditional vaccine development can be outpaced by viral spread. Initially misidentified in a new geographical region, valuable time was lost in determining the exact nature of the pathogen. This delay, estimated to be several months, allowed the virus to spread across Guinea, Sierra Leone, and Liberia, resulting in approximately 11,300 deaths. The extended period required to identify the virus and subsequently begin vaccine development efforts meant that the virus had already established a significant foothold, a scenario that the new AI-aided technology aims to prevent.
Challenges in Targeting Universal Viral Families

The "historic" nature of conventional vaccines means they are often designed to target specific variants of a virus that were prevalent at the time of development. As new variants emerge, these vaccines may offer reduced protection. This is because the surface proteins or antigens that the immune system is trained to recognise may have changed. The new AI-aided technology, in contrast, seeks to identify conserved regions across an entire family of viruses, creating a "master key" that could offer broader and more durable protection against a range of related pathogens, rather than just a single historical strain.

Reading history

Hide →

This history is cleared when the page is closed.

How do “historic” vaccines fail when new strains emerge quickly?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends